Wilkins E, Fisher M, Brogan AJ, Talbird SE, La EM. Cost-effectiveness analysis of tenofovir/emtricitabine and abacavir/lamivudine in combination with efavirenz or atazanavir/ritonavir for treatment-naïve adults with HIV-1 infection in the UK, based on the AIDS Clinical Trials Group 5202 clinical trial. HIV Med. 2016 Aug;17(7):505-15. doi: 10.1111/hiv.12349
Nash Smyth E, La E, Talbird S, Li L, Kaye JA, Lin AB, Bowman L. Treatment patterns and health care resource use (HCRU) associated with repeatedly treated metastatic squamous cell carcinoma of the head and neck (SCCHN) in the United Kingdom (UK). Poster presented at the 2015 ISPOR 18th Annual European Congress; November 9, 2015. Milan, Italy.
Talbird SE, Brogan AJ, La EH, Perard R. Cost-effectiveness analysis of tenofovir/emtricitabine and abacavir/lamivudine in combination with efavirenz or atazanavir/ritonavir for treatment-naïve adults with HIV-1 infection in France and Spain. Poster presented at the Health Technology Assessment international; June 14, 2015. Oslo, Norway.
Talbird SE, Mauskopf JA, Yang K. Review of cost-effectiveness analyses of varicella vaccination: which model structure assumptions and input parameters matter? Poster presented at the 2015 ISPOR 20th Annual International Meeting; May 2015. Philadelphia, PA.
Talbird SE, Graham JB, Mauskopf JA, Masseria C, Krishnarajah G. Impact of tetanus, diphtheria, and acellular pertussis (Tdap) vaccine use in wound management on health care costs and pertussis cases. J Manag Care Pharm. 2015 Jan;21(1):88-99.
Antela A, Llibre JM, Lopez Bernaldo De Quiros JC, Portilla J, Gallois A, Campbell A, Penafiel J, Brogan AJ, Talbird SE. HIV Treatment Cost-Effectiveness Study Group. An economic model to assess the cost-effectiveness of early treatment initiation for people with HIV infection in Spain. Poster presented at the Third National GESIDA Congress; November 2011. Seville, Spain.
Talbird S, Knerer G, Hausdorff W, Taylor T, Frostad CR. Reply to Strutton et al.: response to “Outcomes and costs associated with PHiD-CV, a new protein D conjugate pneumococcal vaccine, in four countries”. Vaccine. 2011 Oct 1;29(44):7591-2.
Deniz B, Brogan AJ, Miller JD, Talbird SE, Thompson JR. Projections using decision-analytic modeling of long-term clinical value of telaprevir for the treatment of HCV patients who had failed prior peginterferon/ribavirin treatment. Poster presented at the 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) Conference; November 2011. San Francisco, CA. [abstract] Hepatology. 2011 Oct 1; 54(Suppl. 1):802A-3A.
Deniz B, Brogan AJ, Miller JD, Talbird SE, Thompson J. Cost-effectiveness assessment of telaprevir combination treatment compared to pegylated-interferon + ribavirin alone in the management of chronic hepatitis C in patients who failed a prior pegylated-interferon + ribavirin treatment. Poster presented at the Annual Scientific Meeting of the American College of Gastroenterology; October 2011.
Brogan AJ, Talbird SE, Cohen C. Cost-effectiveness of nucleoside reverse transcriptase inhibitor pairs in efavirenz-based regimens for treatment-naïve adults with HIV infection in the United States. Value Health. 2011 Jul 1;14(5):657-554.
Aragãgo F, Vera J, Vaz Pinto I, Talbird SE, Brogan AJ. Economic evaluation of early antiretroviral treatment for HIV-1 infected individuals in Portugal. Poster presented at the 6th Annual Conference of the International AIDS Society; July 2011.
Brogan AJ, Miller JD, Talbird SE, Thompson J, Deniz B. Long-term clinical value of telaprevir for treatment of treatment-naïve and treatment-experienced patients with hepatitis C virus infection: projections using decision-analytic modeling. Poster presented at the 2011 Digestive Disease Week; May 9, 2011. Chicago, IL.